Old Articles: <Older 8251-8260 Newer> |
|
Chemistry World January 20, 2012 Sarah Houlton |
Takeda slashes 10% of its workforce This represents about 10% of its workforce, and the cuts will be made in research, commercial and admin sections of the business. |
The Motley Fool January 20, 2012 Brian Orelli |
19 Clinical Trials Aren't Enough The FDA rejects Bristol-Myers and AstraZeneca's dapagliflozin. |
The Motley Fool January 20, 2012 Seth Jayson |
Intuitive Surgical Beats Up on Analysts Yet Again For the quarter ended Dec. 31, Intuitive Surgical beat expectations on revenues and beat expectations on earnings per share. |
The Motley Fool January 20, 2012 Seth Jayson |
ZOLL Medical Beats Up on Analysts Yet Again For the quarter ended Jan. 1, ZOLL Medical met expectations on revenue and beat expectations on earnings per share. |
The Motley Fool January 20, 2012 Seth Jayson |
UnitedHealth Group Beats Estimates Yet Again For the quarter ended Dec. 31, UnitedHealth Group met expectations on revenues and crushed expectations on earnings per share. |
The Motley Fool January 20, 2012 Dan Caplinger |
Can Geron Recover in 2012? Let's look at this year's prospects for this company. |
The Motley Fool January 19, 2012 Sean Williams |
No Vacancy: Workers Need Not Apply to This Sector Pharmaceutical and biotech layoffs are kicking into high gear. |
The Motley Fool January 19, 2012 Brian Orelli |
New Hep C Data Impressive, but It's Not There Yet All-oral treatment still has a ways to go. |
The Motley Fool January 19, 2012 Anders Bylund |
Can This Moat Still Stave Off Invading Hordes? A closer look at Intuitive Surgical's competition only confirms the thesis: this moat is safe as houses. |
The Motley Fool January 18, 2012 Brian Orelli |
2 High-Flying Biotechs Face a New Hurdle The next number-one concern for Aeterna Zentaris' and Keryx's investors should be whether the drug passes its clinical trial. |
<Older 8251-8260 Newer> Return to current articles. |